New data show significant improvements in lung function using combination of tiotropium and olodaterol* in COPD patients

Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol significantly improved lung function (FEV₁^† ) over 24 hours in COPD patients compared to olodaterol alone.¹

Significant improvements were seen for all combinations of doses tested (tiotropium 1.25, 2.5 and 5 μg / olodaterol 5 μg, 10 μg) compared with the respective olodaterol monotherapies.¹ Both treatments were administered using the patient-preferred^2-5 Respimat® Soft Mist^TM Inhaler (SMI) device.

After 4 weeks of treatment, the combination of tiotropium and olodaterol provided an average lung function improvement compared to the pre-treatment baseline of up to 342 mL over the first 6 hours (FEV₁ AUC_0-6) and improvements in trough FEV₁^‡ of up to 166 mL.

Compared to olodaterol monotherapy, the combination of tiotropium and olodaterol further increased lung function by up to 144 mL (FEV₁ AUC_0-6) and 84 mL (trough FEV₁).